Clinical Trial Detail

NCT ID NCT03393845
Title Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients
Recruitment Recruiting
Gender
Phase Phase II
Variant Requirements yes
Sponsors Nancy Chan, MD
Indications

Her2-receptor negative breast cancer

Therapies

Fulvestrant + Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST